Retatrutide

What is Retatrutide

Retatrutide, also known by the code LY3437943, is a synthetic 39-amino-acid peptide developed by Eli Lilly. It belongs to the incretin family, the same family as semaglutide and tirzepatide, but it adds a third receptor target. Phase 2 trials in obesity and type 2 diabetes are complete and the Phase 3 TRIUMPH program is reading out, with TRIUMPH-4 in knee osteoarthritis reporting about 28.7 percent weight reduction at 68 weeks.

We supply it as a lyophilized (freeze-dried) powder for laboratory research, with a batch-specific third-party certificate of analysis.

How it works

Retatrutide activates three metabolic receptors at the same time:

• GLP-1 receptor: slows stomach emptying and signals fullness
• GIP receptor: improves how cells respond to insulin and shifts how lipids are processed
• Glucagon receptor: raises energy expenditure and pushes the liver to burn fat

Single-agonist peptides like semaglutide hit only the first receptor. Dual agonists like tirzepatide hit the first two. Adding the glucagon arm is what lets retatrutide drive the larger weight reduction and the liver-fat drop seen in trials. The three signals work together: appetite goes down, insulin response goes up, and the body burns more energy at rest.

Often studied alongside

Combined-peptide research often pairs retatrutide with growth-hormone-axis peptides such as tesamorelin, which is itself studied for visceral fat reduction, or with AOD-9604, a fragment of growth hormone investigated for fat metabolism. Both are available in research-grade form below.

For reconstitution, the standard solvent in published protocols is bacteriostatic or sterile water.

Documentation